PCM
NVCR icon

Peregrine Capital Management’s NovoCure NVCR Stock Holding History

Peregrine Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-40,095
Closed -$2.41M – 327
2023
Q1 		$2.41M Buy
40,095
+7,183
+22% +$574K 0.07% 245
2022
Q4 		$2.41M Sell
32,912
-7,918
-19% -$596K 0.08% 240
2022
Q3 		$3.1M Sell
40,830
-2,268
-5% -$177K 0.1% 243
2022
Q2 		$3M Sell
43,098
-27
-0.1% -$2.03K 0.09% 247
2022
Q1 		$3.57M Sell
43,125
-3,139
-7% -$231K 0.08% 251
2021
Q4 		$3.47M Buy
46,264
+8,898
+24% +$893K 0.07% 253
2021
Q3 		$4.34M Sell
37,366
-7,381
-16% -$1.12M 0.09% 251
2021
Q2 		$9.93M Sell
44,747
-28,133
-39% -$5.47M 0.18% 232
2021
Q1 		$9.63M Sell
72,880
-2,917
-4% -$461K 0.18% 235
2020
Q4 		$13.1M Sell
75,797
-50,699
-40% -$6.94M 0.25% 192
2020
Q3 		$14.1M Sell
126,496
-62,908
-33% -$5.03M 0.37% 102
2020
Q2 		$11.2M Buy
189,404
+38,715
+26% +$2.55M 0.32% 120
2020
Q1 		$10.1M Buy
150,689
+554
+0.4% +$43.8K 0.36% 116
2019
Q4 		$12.7M Sell
150,135
-1,807
-1% -$146K 0.32% 128
2019
Q3 		$11.4M Sell
151,942
-50,675
-25% -$4.05M 0.31% 130
2019
Q2 		$12.8M Sell
202,617
-23,088
-10% -$1.17M 0.32% 134
2019
Q1 		$10.9M Sell
225,705
-157,716
-41% -$7.59M 0.27% 145
2018
Q4 		$12.8M Sell
383,421
-75,138
-16% -$2.75M 0.36% 125
2018
Q3 		$24M Sell
458,559
-412,470
-47% -$16.4M 0.57% 69
2018
Q2 		$27.3M Sell
871,029
-51,439
-6% -$1.43M 0.68% 45
2018
Q1 		$20.1M Buy
922,468
+56,797
+7% +$1.22M 0.49% 73
2017
Q4 		$17.5M Buy
865,671
+238,195
+38% +$4.59M 0.41% 95
2017
Q3 		$12.5M Sell
627,476
-218,560
-26% -$4.3M 0.3% 132
2017
Q2 		$14.6M Sell
846,036
-364,898
-30% -$4.71M 0.36% 105
2017
Q1 		$10.1M Buy
1,210,934
+83,448
+7% +$603K 0.26% 157
2016
Q4 		$8.85M Buy
1,127,486
+192,178
+21% +$1.55M 0.23% 203
2016
Q3 		$7.99M Buy
+935,308
New +$8.53M 0.21% 217

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Peregrine Capital Management's NVCR Position: Q2 2023 in Review

Peregrine Capital Management sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 40,095 shares — an estimated $2.41M sold.

Peregrine Capital Management first reported a position in NVCR in Q3 2016 and held it in 27 quarters. The position peaked at $27.3M in Q2 2018. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

  • Peregrine Capital Management reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
  • Peregrine Capital Management sold 40,095 NovoCure shares in Q2 2023, an estimated $2.41M.
  • Peregrine Capital Management first reported a position in NovoCure in Q3 2016 and held it in 27 quarters.
  • Peregrine Capital Management's NovoCure position peaked at $27.3M in Q2 2018.
  • 267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Peregrine Capital Management's 13F filing for Q2 2023, filed 26 Jul 2023.